Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jiaxin Niu"'
Autor:
Kiyotaka Yoh, Dusan Kotasek, David R. Spigel, Drew W. Rasco, Rachel Altura, Corinne Maurice-Dror, Dae Ho Lee, Martin Gutierrez, Byoung Chul Cho, Adnan Nagrial, Jiaxin Niu, Myung-Ju Ahn, Yixin Ren, Dong Wan Kim, S. Siddiqi, Jair Bar, Ruth Perets, Miyako Satouchi
Publikováno v:
Lung Cancer. 159:162-170
This first-in-human phase I study (NCT03179436) investigated anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody quavonlimab and anti-programmed death 1 monoclonal antibody pembrolizumab in patients with advanced solid tumors. The st
Autor:
George J. Weiner, Heather Kelley, Geoffrey T. Gibney, Montaser Shaheen, Mohammed M. Milhem, Theresa Medina, Yousef Zakharia, Elizabeth I. Buchbinder, Luping Zhao, Jason J. Luke, John M. Kirkwood, Adil Daud, Diwakar Davar, James E. Wooldridge, Antoni Ribas, Jiaxin Niu, Anthony J. Olszanski, Dmitri Bobilev, Takami Sato, Hong Liu, Bartosz Chmielowski, Kim Margolin, Inderjit Mehmi, Arthur M. Krieg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThere are limited therapeutic options for patients with progressive disease (PD) on or after PD-1–blocking antibody therapy. Vidutolimod (CMP-001) is a first-in-class, immunostimulatory virus-like particle containing a CpG-A Toll-like rec
Autor:
Ze-Jiaxin Niu, Dan-Feng Ren, Chun-Hua Li, Ming-Fei Du, Yang Wang, Ke-Ke Wang, Jie Zhang, Ke Gao, Yong-Xing Wu, Wei-Hua Gao, Jianjun Mu, Yue Sun, Shi Yao, Yue-Yuan Liao, Tie-Lin Yang, Lan Wang, Chen Chen, Ting Zou, Rui-Chen Yan, Gui-Lin Hu, Xi Zhang, Hao Li, Hao Jia, Dan Wang, Yu Yan, Chao Chu, Qiong Ma, Zi-Yue Man
Publikováno v:
Journal of clinical hypertension (Greenwich, Conn.). 23(12)
Corin, a transmembrane serine protease that can cleave pro-atrial natriuretic peptide (Pro-ANP) into smaller bioactive molecule atrial natriuretic peptide, has been shown to be involved in the pathophysiology of hypertension, cardiac hypertrophy. We
Publikováno v:
Current Oncology Reports. 23
Both anti-angiogenesis and immunotherapy are well-established therapeutic options in solid tumors. Here, we review the rationale as well as clinical evidence of combining these two approaches. There is strong rationale and substantial preclinical and
Autor:
Adil Daud, Mohammed M. Milhem, Riyue Bao, Yousef Zakharia, Jiaxin Niu, Geoffrey T. Gibney, David Mauro, Kim Margolin, Arthur M. Krieg, Antoni Ribas, Heather Kelley, Anthony J. Olszanski, Elizabeth I. Buchbinder, Jason J. Luke, Diwakar Davar, Theresa Medina, John M. Kirkwood, Aaron H. Morris, Katie M. Campbell, Montaser Shaheen, Inderjit Mehmi, James E. Wooldridge, George J. Weiner, Takami Sato
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Therapeutic options are limited for patients with advanced melanoma that is refractory to PD-1 blockade. This study was performed in this patient population to assess the safety and antitumor activity of CMP-001, a CpG-A TLR9 agonist packa
Autor:
Adil Daud, Montaser Shaheen, David J. Mauro, Geoffrey T. Gibney, Interjit Mehmi, Antoni Ribas, Kim Margolin, Mohammed M. Milhem, Arthur M. Krieg, Takami Sato, Elizabeth I. Buchbinder, Yousef Zakharia, John M. Kirkwood, Diwakar Davar, Aaron Morris, Katie M. Campbell, Riyue Bao, Theresa Medina, George J. Weiner, Jiaxin Niu, Anthony J. Olszanski, Jason Luke
Publikováno v:
Oral Presentations.
Background Intratumoral (IT) injection of CMP-001, a CpG-A TLR9 agonist packaged within a virus-like particle, is designed to activate tumor-associated plasmacytoid dendritic cells, inducing an interferon-rich tumor microenvironment and anti-tumor CD
Autor:
S.T. Laroia, John V. Heymach, J.E. Woolridge, Jiaxin Niu, Arthur M. Krieg, H. Kelley, David J. Mauro, Vassiliki A. Papadimitrakopoulou, Alda L. Tam, G. Walker, A.C. Price, L. Vora, Anne Tsao, Jose M. Pacheco, Marcelo V. Negrao, Erminia Massarelli, Muhammad Furqan
Publikováno v:
Journal of Thoracic Oncology. 16:S196
Autor:
Rene Gonzales, Jiaxin Niu, Jason J. Luke, Theresa Medina, Aaron H. Morris, Antoni Ribas, David J. Mauro, John M. Kirkwood, Kim Margolin, Elizabeth I. Buchbinder, Mohammed M. Milhem, Arthur M. Krieg, Inderjit Mehmi, Ryan M. Weight, Montaser Shaheen
Publikováno v:
Cancer Research. 78:CT144-CT144
Background: CMP-001 comprises a CpG-A oligodeoxynucleotide packaged within a virus-like particle. It is designed to activate tumor-associated plasmacytoid dendritic cells via TLR9 inducing an interferon-rich tumor microenvironment and anti-tumor CD8+